Rilparencel (Renal Autologous Cell Therapy)
Advanced Chronic Kidney Disease (CKD) in patients with Type 2 Diabetes at high risk of kidney failure
Key Facts
Indication
Advanced Chronic Kidney Disease (CKD) in patients with Type 2 Diabetes at high risk of kidney failure
Phase
Phase 3
Status
Active
Company
About ProKidney
ProKidney is focused on transforming the treatment of chronic kidney disease through its proprietary renal autologous cell therapy, rilparencel. The company is advancing this therapy in a pivotal Phase 3 program (PROACT 1) for patients with advanced CKD and type 2 diabetes, following promising Phase 2 results. With over 35 million U.S. adults affected by CKD and approximately 135,000 progressing to dialysis annually, ProKidney aims to provide a therapeutic option to delay disease progression and the need for renal replacement therapy.
View full company profile